HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · Retatrutide 20mg + Tirzepatide 40mg
Dual-incretin research blend · research-use
Retatrutide + Tirzepatide blend supply.
Co-formulated 60 mg research vials (retatrutide 20 mg / tirzepatide 40 mg) with per-lot HPLC purity and mass-spec identity documentation, for laboratory and private-label programs.
!
Research use — supplied as research peptides; buyers confirm local compliance
On 2026-04-30 the FDA proposed removing GLP-1 medications from the regulatory bulk-substance framework. Pending finalization, US regulated bulk-substance facilities cannot compound these from bulk substances. Pepti positions GLP-1 compounds for research and private-label brand evaluation worldwide. Read the GLP-1 2026 update →
Retatrutide 20mg + Tirzepatide 40mgHPLC ≥ 99%MS confirmed60mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Retatrutide 20mg + Tirzepatide 40mg |
|---|---|
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 60mg |
| Documentation | Batch-document availability confirmed by product, specification and applicable lot |
| Distribution scope | Research use, worldwide |
| Storage | Store the lyophilized blend at -20 °C, protected from light and moisture in a desiccated, sealed container. After reconstitution keep at 2-8 °C and use within the validated stability window. Ships under cold chain / with ice packs. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat | 2,000+ vials | 21–28 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
About Retatrutide 20mg + Tirzepatide 40mg.
The product is a physical co-formulation of two incretin-class peptides: retatrutide (LY3437943), a triple agonist at the GLP-1, GIP and glucagon receptors, and tirzepatide (LY3298176), a dual GIP/GLP-1 receptor agonist. Because it is a blend rather than a single molecule it carries no combined CAS, molecular formula or molecular weight; each peptide retains its own identity and is characterized separately on the certificate of analysis.
Documentation
Batch documentation support for Retatrutide 20mg + Tirzepatide 40mg lots.
batch-document availability confirmed by product, specification and applicable lot. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the Retatrutide 20mg + Tirzepatide 40mg reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
Retatrutide 20mg + Tirzepatide 40mg — frequently asked by B2B buyers.
What exactly is in the Retatrutide 20 mg + Tirzepatide 40 mg vial?
Each 60 mg vial is a physical co-formulation of 20 mg retatrutide and 40 mg tirzepatide presented as a single lyophilized cake. It is not a novel single molecule, so it carries no combined CAS or molecular weight; both peptides are documented individually on the certificate of analysis.
What documentation ships with each lot?
A per-lot certificate of analysis reporting HPLC purity for each peptide and identity confirmation by mass spectrometry (MS), together with appearance, water/residual-solvent and endotoxin (only if specifically ordered and tested) data available on request. Third-party lab verification can be arranged for qualified buyers.
What are the minimum order quantity and available formats?
The catalog format is the 60 mg co-formulated vial (retatrutide 20 mg / tirzepatide 40 mg) at a 50-vial MOQ. Alternative ratios, single-component vials, different fill volumes and bulk lyophilized powder are quoted via RFQ for OEM and private-label programs.
Can the ratio and labeling be customized for private-label?
Yes. As an OEM/private-label supplier we can adjust the retatrutide-to-tirzepatide ratio, vial fill and unbranded labeling and packaging to buyer specification, subject to documentation and destination-market compliance review.
Is this product intended for therapeutic or consumer use?
No. All material is supplied strictly for laboratory research and as a manufacturing input. Retatrutide and tirzepatide are incretin-class compounds subject to regulatory restrictions; the buyer is responsible for compliance in their jurisdiction and must not represent the product for consumer use.
Related compounds
Related research peptides.
COA library search
Search public COAs for this product.
The public COA library is being expanded by product and specification. Use the search link below to check current public records for this item.